The patent describes the extraction and standardization of stable doses of psychedelic compounds
The Company also reports first quarter 2022 financial results and operational highlights
Vancouver, British Columbia, May 18, 2022 – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a second patent by the United States Patent and Trademark Office (USPTO) for the extraction and standardization of natural psilocybin and associated psychedelic compounds. The patent describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized drug candidates.
“The issuance of Filament’s first US patent is a testament to the strength of our drug development platform,” said Benjamin Lightburn, Chief Executive Officer. “This approval represents important progress for our intellectual property portfolio.”
Filament has developed innovative technology to extract and standardize stable doses of natural compounds from magic mushrooms. The Company currently holds five patents, including the first-ever patent for the extraction and standardization of natural psilocybin, which was issued on August 3, 2021.
First Quarter Financial Results and Operational Highlights:
Filament released its first quarter financial results and operational highlights for the period ended March 31, 2022. Financial results and operational highlights from the Company’s first quarter of 2022 and subsequent period include:
- Cash and cash equivalents of over $3.6 million;
- Issued patents by the Canadian Intellectual Property Office and the United States Patent and Trademark Office patents for the extraction and standardization of natural psilocybin;
- Held a pre-investigational new drug application meeting with the United States Food and Drug Administration discussing Filament’s natural psychedelic drug candidates, drug development strategy and long-term plans;
- Entered into a licensing agreement with Cybin Therapeutics to license and provide Filament’s proprietary botanical drug candidate, PEX010 (25mg), for two Phase II clinical trials with, one of which has received Health Canada authorization;
- Entered into a licensing agreement with ATMA Journey Centers to provide PEX010 (25mg) for use in a Phase I safety trial, for which ATMA has received Health Canada authorization;
- Entered into a licensing agreement with Psyence Group Inc. to provide PEX010 (25mg) and the associated intellectual property for use in Psyence’s upcoming clinical trials in the United Kingdom.
ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary technology platform enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.
Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.
MEDIA RELATIONS
Anna Cordon, Director of Communications
778.245.9067
anna@filament.health
INVESTOR RELATIONS CONTACT
KCSA Strategic Communications
Adam Holdsworth
347.487.6788
KCSA-investor-relations@filament.health
FORWARD LOOKING INFORMATION
Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning Filament’s upcoming clinical trials; strategic and growth plans of the Company including intellectual property; and the impact, timing and accessibility of psychedelic treatments. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QSMay 18, 2022
.jpg)
